Axonics, Inc. (AXNX) is a publicly traded company in the Healthcare sector, operating within the Medical - Devices industry. The company is headquartered in Irvine, CA, United States. The current CEO is Raymond W. Cohen.
AXNX has IPO date of 2018-10-31, 797 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $3.63B.
Axonics, Inc. is a medical technology company that develops and commercializes sacral neuromodulation (SNM) systems to treat bladder and bowel dysfunction disorders, including overactive bladder, urinary incontinence, and fecal incontinence. The company's proprietary rechargeable SNM system delivers mild electrical pulses to the sacral nerve to restore normal communication between the bladder, bowel, and brain. In addition to its SNM platform, Axonics offers Bulkamid, a urethral bulking agent for treating female stress urinary incontinence. The company markets its products through a direct sales force and distributor network across the United States, United Kingdom, Germany, the Netherlands, Nordic countries, and other international markets.
